QUICK SEARCH:   [advanced]
Author:
Keyword(s):
Year:  Vol:  Page: 

   

 

Health Affairs, 24, no. 3 (2005): 706-717
doi: 10.1377/hlthaff.24.3.706
© 2005 by Project HOPE
 
New Online
 * Senate Health Reform Bill
 * Rewarding Providers
 * Public Option Policy Brief
 * Health Reform & Abortion
 * Delivery System Reform
This Article
* Full Text (HTML)
* Reprint (PDF)
* Supplemental Exhibits
* Submit a response to this article
* Alert me when this article is cited
* Alert me when Comments are posted
* Alert me if a correction is posted
Services
* E-mail this article to a friend
* Similar articles in this journal
* Similar articles in Web of Science
* Similar articles in PubMed
* Alert me to new issues of the journal
* Add to My Personal Archive
* Download to Citation Manager
*Reprints & Permissions
Citing Articles
* Citing Articles via HighWire
* Citing Articles via Web of Science (9)
* Citing Articles via Google Scholar
Google Scholar
* Articles by Danzon, P. M.
* Articles by Tejwani, S. S.
* Search for Related Content
PubMed
* PubMed Citation
* Articles by Danzon, P. M.
* Articles by Tejwani, S. S.
Related Collections
* Health Promotion/Disease Prevention
* International Issues
* Public Health
* Research And Technology
* Consumer Issues
* Vaccines

Implementation

Vaccine Supply: A Cross-National Perspective

Patricia M. Danzon, Nuno Sousa Pereira and Sapna S. Tejwani

In U.S. vaccine markets, competing producers with high fixed, sunk costs face relatively concentrated demand. This tends to lead to exit of all but one or very few producers per vaccine. Detailed evidence of exits and shortages in the flu vaccine market demonstrates the importance of high fixed costs, demand uncertainty, and dynamic quality competition. A comparison of vaccine suppliers in four industrialized countries compared with the United States shows that smaller foreign markets often have more and different vaccine suppliers. High, country-specific, fixed costs, combined with price and volume uncertainty, plausibly deters these potential suppliers from attempting to enter the U.S. market.


Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati    What's this?


This article has been cited by other articles:


Home page
AJPHHome page
B.-K. Yoo, M. Kasajima, K. Fiscella, N. M. Bennett, C. E. Phelps, and P. G. Szilagyi
Effects of an Ongoing Epidemic on the Annual Influenza Vaccination Rate and Vaccination Timing Among the Medicare Elderly: 2000-2005
Am J Public Health, October 1, 2009; 99(S2): S383 - S388.
[Abstract] [Full Text] [PDF]


Home page
MSOMHome page
S. Deo and C. J. Corbett
Cournot Competition Under Yield Uncertainty: The Case of the U.S. Influenza Vaccine Market
MSOM, October 1, 2009; 11(4): 563 - 576.
[Abstract] [PDF]


Home page
JAMAHome page
L. O. Gostin
Medical Countermeasures for Pandemic Influenza: Ethics and the Law
JAMA, February 1, 2006; 295(5): 554 - 556.
[Full Text] [PDF]


Home page
JAMAHome page
M. M. Mello and T. A. Brennan
Legal Concerns and the Influenza Vaccine Shortage
JAMA, October 12, 2005; 294(14): 1817 - 1820.
[Full Text] [PDF]


Home page
Health Aff (Millwood)Home page
P. Danzon and N. S. Pereira
Why Sole-Supplier Vaccine Markets May Be Here To Stay
Health Aff., May 1, 2005; 24(3): 694 - 696.
[Abstract] [Full Text] [PDF]



Home | Current Issue | Archives | Topic Collections | Search | Blog | Subscribe | Contact Us | Help

© 2001-2005 Project HOPE–The People-to-People Organization
Terms and Policies